The Netherlands Foundation for the Detection of Hereditary Tumours, Rijnsburgerweg 10, Poortgebouw Zuid, 2333 AA Leiden, The Netherlands.
Br J Cancer. 2011 Jan 4;104(1):37-42. doi: 10.1038/sj.bjc.6605997. Epub 2010 Nov 9.
The optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial adenomatous polyposis (FAP) patients.
Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological treatment was evaluated for all desmoids.
Median follow-up was 8 years. For intra-abdominal desmoids (n=62), PFS rates at 10 years of follow-up were comparable after surgical and non-surgical treatment (33% and 49%, respectively, P=0.163). None of these desmoids could be removed entirely. Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin combination therapy.
For intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred after combinations including doxorubicin.
纤维瘤病的最佳治疗方法存在争议。我们评估了荷兰家族性腺瘤性息肉病(FAP)患者的纤维瘤病的治疗方法。
从荷兰息肉病登记处确定了 78 例患有纤维瘤病的 FAP 患者。回顾性分析了纤维瘤形态、治疗和结局的数据。分别对手术与非手术治疗、腹腔内和腹腔外纤维瘤病进行了无进展生存率(PFS)和最终结局的比较。还评估了所有纤维瘤病的药物治疗。
中位随访时间为 8 年。对于腹腔内纤维瘤病(n=62),10 年随访时手术和非手术治疗的 PFS 率相似(分别为 33%和 49%,P=0.163)。这些纤维瘤病都不能完全切除。最终,五分之一的患者死于纤维瘤病。大多数腹腔外和腹壁纤维瘤病采用手术治疗,PFS 率为 63%,无纤维瘤病死亡。非甾体抗炎药和抗雌激素治疗的比较显示出相似的结果。接受化疗的 10 例患者中有 4 例肿瘤生长稳定,均在多柔比星联合治疗后。
对于腹腔内纤维瘤病,保守治疗和手术治疗的结果相似。对于腹腔外和腹壁纤维瘤病,手术似乎是合适的。不同的药物治疗显示出相似的结果。如果对进行性生长的腹腔内纤维瘤病进行化疗,最有利的结果发生在包括多柔比星的联合治疗后。